Investors looking to participate in Zydus Lifesciences’ share buyback worth Rs 1,100 crore will likely have to purchase the shares of the company latest by Wednesday, May 27, before the stock goes ex-record date for the corporate action on Friday.
The pharma company fixed the record date to determine shareholder eligibility for the corporate action on May 29 (Friday). Only those shareholders who own the shares of the company in their demat accounts as on the record date will be eligible to tender shares.
As per SEBI's T+1 settlement norm, investors must buy the company's shares at least one trading day before the record date so that they are credited to their demat accounts by that date, making them eligible for the reward.
However, markets will remain closed on May 28 (Thursday) on account of Bakri Id. This effectively makes May 27 (Wednesday) the last date to buy the shares so that they are credited to the shareholders’ accounts by the record date (Friday).
All about Zydus Lifesciences share buyback
Earlier this month, Zydus Lifesciences board approved the plan to buy back up to 95.65 lakh shares, each with a face value of Re 1, representing 0.95% of the company’s paid-up equity share capital, for an aggregate amount not exceeding Rs 1,100 crore. The buyback will be conducted via the tender route.
Also Read | Zydus Lifesciences' Rs 1,100 crore share buyback at 13% premium: Check record date, other details
The price for Zydus Lifesciences' biggest-ever share buyback was fixed at Rs 1,150 apiece, implying a premium of nearly 7% from the stock’s previous closing price of Rs 1,079.05 apiece.
Zydus Lifesciences’ board of directors also approved the formation of a buyback committee, which can increase the buyback price or reduce the number of shares to be bought back up to one day before the record date, without changing the overall buyback size. Other details, including the entitlement ratio and whether the promoter and promoter group will participate in the buyback, will be disclosed later.
Zydus Lifesciences share buyback history
This follows the pharma company’s Rs 600 crore share buyback conducted via the tender route at a price of Rs 1,005 per share. The buyback price implied a premium of nearly 9% over the stock’s trading level on the record date. Prior to that, the company had executed a Rs 750 crore share buyback in 2022.
Also Read | Last date to buy Bajaj Auto, GSK Pharma and 10 other stocks for dividends
Zydus Lifesciences shareholding pattern
Before the buyback announcement, the promoter and promoter group held nearly a 75% stake in Zydus Lifesciences as of May 15, 2026, while retail investors and mutual funds held around 5% each. Foreign portfolio investors owned nearly 7% of the company, while insurance companies held slightly over 6%.
Zydus Lifesciences Q4 results
Zydus Lifesciences reported a consolidated net profit of Rs 1,272.5 crore for the January-March quarter of FY26, marking a 9% increase from the Rs 1,171 crore profit reported in the corresponding quarter of the previous financial year.
The company’s revenue from operations rose more than 16% year-on-year to Rs 7,587 crore during the quarter under review, compared with Rs 6,528 crore in the year-ago period.
Along with the Q4 results and share buyback announcement, Zydus Lifesciences said its board has recommended a final dividend of Re 1 per share (100%) on a face value of Re 1 each, subject to shareholders’ approval at the company’s Annual General Meeting scheduled for August 11.
Also Read | Zydus Lifesciences shares soar 7% to fresh record high after Q4 results. Should you buy, sell or hold?
Zydus Lifesciences share price
Zydus Lifesciences shares have gained over 4% in one week and 15% in one month. The stock is up more than 18% so far in 2026.
In the longer term, the shares of the company have gained over 18% in one year, 113% in three years and around 73% in five years. The company currently has a market capitalisation of nearly Rs 1.09 lakh crore.
Also read | LIC 1:1 bonus bonanza! Is today the last day to buy shares for free rewards?
(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of The Economic Times)
